{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:26:39Z","timestamp":1787667999436,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12149-026-02225-w","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:29:00Z","timestamp":1779701340000},"page":"1138-1145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Target-anchored platform concentration and uneven developmental consolidation in systemic solid-tumor radioligand therapy: a retrospective Trialtrove-based analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9381-5189","authenticated-orcid":false,"given":"Yue","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2225_CR1","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12149-025-02090-z","volume":"39","author":"T Watabe","year":"2025","unstructured":"Watabe T, Hirata K, Iima M, Yanagawa M, Saida T, Sakata A, et al. Recent advances in theranostics and oncology PET: emerging radionuclides and targets. Ann Nucl Med. 2025;39:909\u201321. https:\/\/doi.org\/10.1007\/s12149-025-02090-z.","journal-title":"Ann Nucl Med"},{"key":"2225_CR2","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","volume":"52","author":"HH Tran","year":"2025","unstructured":"Tran HH, Yamaguchi A, Manning HC. Radiotheranostic landscape: A review of clinical and preclinical development. Eur J Nucl Med Mol Imaging. 2025;52:2685\u2013709. https:\/\/doi.org\/10.1007\/s00259-025-07103-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2225_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"2225_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"2225_CR5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00259-025-07083-8","volume":"52","author":"R Laudicella","year":"2025","unstructured":"Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A, et al. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:2723\u201335. https:\/\/doi.org\/10.1007\/s00259-025-07083-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2225_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.2967\/jnumed.124.269444","volume":"66","author":"C Morgat","year":"2025","unstructured":"Morgat C, Duan H, Dalm S, Hindie E, Gunther T, Krause BJ, et al. A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry. J Nucl Med. 2025;66(8):1160\u20137. https:\/\/doi.org\/10.2967\/jnumed.124.269444.","journal-title":"J Nucl Med"},{"key":"2225_CR7","doi-asserted-by":"publisher","first-page":"1737443","DOI":"10.3389\/fnume.2025.1737443","volume":"5","author":"X Wu","year":"2025","unstructured":"Wu X, Wang Y, Li Y, Hu W. Recent clinical advances in fibroblast activation protein targeted radioligand therapy for solid tumors. Front Nucl Med. 2025;5:1737443. https:\/\/doi.org\/10.3389\/fnume.2025.1737443.","journal-title":"Front Nucl Med"},{"key":"2225_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40336-025-00733-9","volume":"13","author":"H Roustaei","year":"2025","unstructured":"Roustaei H, D\u2019Alessandria C, Decristoforo C. Navigating the safety profile of Actinium-225 targeted alpha therapy: a comprehensive review. Clin Transl Imaging. 2025;13:591\u2013605. https:\/\/doi.org\/10.1007\/s40336-025-00733-9.","journal-title":"Clin Transl Imaging"},{"key":"2225_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","volume":"9","author":"EL Hooijman","year":"2024","unstructured":"Hooijman EL, Radchenko V, Ling SW, Konijnenberg M, Brabander T, Koolen SLW, et al. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI Radiopharm Chem. 2024;9:9. https:\/\/doi.org\/10.1186\/s41181-024-00239-1.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"8","key":"2225_CR10","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1007\/s00259-024-06657-2","volume":"51","author":"TNB Pascual","year":"2024","unstructured":"Pascual TNB, Paez D, Iagaru A, Gnanasegaran G, Lee ST, Sathekge M, et al. Guiding principles on the education and practice of theranostics. Eur J Nucl Med Mol Imaging. 2024;51(8):2320\u201331. https:\/\/doi.org\/10.1007\/s00259-024-06657-2.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02225-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02225-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02225-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:43:37Z","timestamp":1787665417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02225-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02225-w","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}